Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
MWN-AI** Summary
Bioxytran, Inc. (OTCQB: BIXT) announced on March 4, 2026, promising results from its recent dose optimization study for the antiviral candidate ProLectin-M, which is moving toward a Phase 3 registrational trial. The results revealed that a daily dosage of 16,800 mg effectively achieved 90% viral clearance by Day 5 in a study of 39 participants, maintaining a favorable safety profile. This dosage has been identified as the optimal regimen, striking a balance between antiviral efficacy and tolerability.
The planned Phase 3 trial aims to recruit approximately 408 participants and will be a randomized, placebo-controlled outpatient study targeting standard-risk patients suffering from mild-to-moderate COVID-19, as well as other viral infections like Influenza and RSV. The primary endpoint will assess significant viral clearance or clinical improvement compared to placebo.
Bioxytran is currently in discussions with the U.S. Food and Drug Administration (FDA) and the Central Drugs Standard Control Organization (CDSCO) in India to finalize trial design elements. ProLectin-M employs a novel mechanism that antagonizes galectins, interfering with viral entry, setting it apart from standard antiviral strategies that target viral replication after infection.
The company is also exploring its galectin antagonist platform for broader antiviral applications. Collaboration with the University of Georgia began recently to evaluate its compound against H5N1 avian influenza strains, while in vitro studies have shown promise against other viral strains.
With dose optimization concluded and regulatory discussions advancing, Bioxytran appears poised to embark on a pivotal Phase 3 trial, aiming for potential regulatory approval of ProLectin-M as a significant antiviral treatment option. Further updates on the trial's progress and timelines are expected as discussions continue.
MWN-AI** Analysis
Bioxytran, Inc. (OTCQB: BIXT) has taken significant strides with its lead antiviral candidate, ProLectin-M, recently announcing positive dose optimization results and advancing toward a pivotal Phase 3 registrational trial. The data confirming the optimal dose of 16,800 mg/day, which achieved 90% viral clearance by Day 5, suggests considerable potential for the therapeutic efficacy of ProLectin-M in treating mild-to-moderate COVID-19 and other viral infections such as Influenza and RSV.
Investors interested in Bioxytran should consider the implications of these developments, particularly the successful dose optimization and positive engagements with regulatory bodies like the FDA and CDSCO. The planned Phase 3 trial, aiming for enrollment of approximately 408 participants, will be a critical step towards full regulatory approval and market entry.
What sets Bioxytran apart is its innovative galectin-blocking mechanism, distinguishing ProLectin-M from traditional antiviral therapies. This strategy focuses on preventing viral entry into host cells rather than inhibiting replication, potentially offering a competitive edge in a crowded antiviral market. Coupled with its favorable safety profile and minimal drug interactions, Bioxytran’s technology could establish itself as a first-line treatment, appealing to both healthcare providers and patients.
The broader applications of this platform also present additional upside, with ongoing research into other viral strains and Long COVID therapies. As such, investors should monitor Bioxytran’s regulatory progress closely and its announcements regarding ongoing research initiatives.
In summary, Bioxytran stands at a pivotal crossroads with substantial upside potential. Investors who are well-versed in biotech may find an attractive play in Bioxytran while keeping an eye on clinical trial timelines and regulatory developments that will be crucial for the stock's performance moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive dose optimization results for its lead antiviral candidate, ProLectin-M, and provided an update on the Company’s planned Phase 3 registrational trial. The data, released March 2, 2026, were designed to establish the optimal dosing strategy and support advancement into a pivotal study intended to enable full regulatory approval.
Phase 3 Registrational Trial Overview
Bioxytran has entered regulatory discussions with the U.S. Food and Drug Administration (FDA) and India’s Central Drugs Standard Control Organization (India regulator) to finalize the design of a Phase 3 registrational trial.
Planned key elements include:
- Study Size: Approximately 408 participants
- Design: Randomized, placebo-controlled, outpatient study
- Primary Endpoint: Statistically significant viral clearance or clinical improvement by Day 5 compared to placebo
- Target Population: Standard-risk patients with mild-to-moderate COVID-19 and other viral infections from Influenza, RSV and other viruses
The Company intends for the Phase 3 trial to serve as the final clinical step toward potential regulatory approval.
Dose Optimization Confirms 16,800 mg/day as Target Regimen
The recently completed 39-participant study confirmed that a 16,800 mg/day dosing regimen achieved 90% viral clearance by Day 5 while maintaining a favorable safety profile.
Earlier development stages evaluated lower dose levels. The March 2 data identified 16,800 mg/day as the optimal balance between antiviral activity and tolerability, providing clarity as the Company advances into Phase 3 planning.
Differentiated Mechanism: Galectin Antagonism
ProLectin-M utilizes a novel galectin-blocking mechanism designed to interfere with viral entry into host cells. This approach differs from replication inhibitors such as Paxlovid, developed by Pfizer, which target viral proteases after infection has occurred.
Bioxytran believes its entry-blocking strategy may offer:
- A potential first-line treatment option for standard-risk patients
- Reduced risk of rebound phenomena observed with certain antiviral classes
- Minimal drug-to-drug interaction concerns to date
- Broad applicability across viral variants due to targeting conserved structural elements involved in viral attachment
Expanding the Platform Beyond COVID-19
Bioxytran is also evaluating the broader antiviral potential of its galectin antagonist platform.
On February 23, 2026, the Company initiated a research collaboration with the University of Georgia to evaluate its compound (PHM23) against H5N1 avian influenza strains as part of a federally supported initiative aimed at mitigating poultry losses.
In addition, in vitro studies have demonstrated viral load reduction against RSV and H1N1 influenza strains. The Company is also advancing ProLectin-I, an intravenous formulation, for investigation in Long COVID.
Corporate Outlook
With dose optimization complete and regulatory engagement underway, Bioxytran believes it has established the scientific and clinical foundation necessary to proceed into a pivotal Phase 3 registrational trial. The Company will provide additional updates as regulatory discussions progress and timelines are finalized.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical-stage biotechnology company developing galectin antagonist therapies for viral diseases and other indications. The Company’s lead product candidate, ProLectin-M, is designed to block viral entry into cells through galectin modulation.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the planned Phase 3 registrational trial, regulatory discussions with the FDA and CDSCO, anticipated trial design, patient enrollment targets, expected endpoints, potential regulatory approval, expansion into additional viral indications, and the therapeutic potential of ProLectin-M and ProLectin-I. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those described. Risks and uncertainties include, among others, the outcome of regulatory discussions, the ability to initiate and complete clinical trial results, regulatory approval processes, market conditions, and other factors described in the Company’s filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to update forward-looking statements except as required by law.
For more information, please visit:
www.bioxytraninc.com
Investor Contact:
David Platt, PhD
CEO, Bioxytran, Inc.
617-484-1199
David.Platt@bioxytraninc.com
SOURCE: BioXyTran, Inc.
FAQ**
How does Bioxytran Inc BIXT plan to address potential risks during the Phase 3 registrational trial considering ongoing regulatory discussions with the FDA and CDSCO?
What strategies does Bioxytran Inc BIXT have in place to recruit the 408 participants needed for the pivotal study targeting standard-risk viral-infected outpatients?
Can Bioxytran Inc BIXT provide details on the expected timeline for the completion of the Phase 3 trial and potential regulatory approval based on current discussions with the FDA and CDSCO?
How does the dosing regimen of 16,800 mg/day for ProLectin-M compare in terms of safety and efficacy against existing antiviral treatments in Bioxytran Inc BIXT's pipeline?
**MWN-AI FAQ is based on asking OpenAI questions about Bioxytran Inc (OTC: BIXT).
NASDAQ: BIXT
BIXT Trading
-19.0% G/L:
$0.0405 Last:
100,055 Volume:
$0.0408 Open:
